KMT2A and neoplasm: Notably, efficient leukemic reprogramming of myeloid progenitors by MLL chimeras requires the action of a MLL antagonist, the Polycomb group (PcG) protein BMI1, to ensure repression of tumor-suppressor genes that would otherwise counteract the effect of the oncogenic fusions 9, 10.